Effect of Combined Use of Ivermectin and Colchicine in COVID-19 Patients
NCT ID: NCT05246072
Last Updated: 2022-04-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
135 participants
INTERVENTIONAL
2021-11-01
2022-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effectiveness and Safety of Ivermectin for the Prevention of Covid-19 Infection in Colombian Health Personnel
NCT04527211
Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria
NCT07235020
Effectiveness of Vaccination Against COVID-19 in Brazil: Case-Control Study
NCT05621928
Study Comparing Moxidectin And Ivermectin In Subjects With Onchocerca Volvulus Infection
NCT00790998
Antihelminthic Therapy Combined With Antimony in the Treatment of Cutaneous Leishmaniasis
NCT00469495
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Ivermectin + colchicine + standard care
In addition to the local standard of care for COVID 19 patients, the patient will receive:
Ivermectin + Colchicine
Ivermectin + colchicine
In addition to the local standard of care for COVID 19 patients, the patient will receive Ivermectin + colchicine
Colchicine + standard care
In addition to the local standard of care for COVID 19 patients, the patient will receive:
Colchicine
Colchicine
In addition to the local standard of care for COVID 19 patients, the patient will receive colchicine
standard care
Patients will receive Standard care
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ivermectin + colchicine
In addition to the local standard of care for COVID 19 patients, the patient will receive Ivermectin + colchicine
Colchicine
In addition to the local standard of care for COVID 19 patients, the patient will receive colchicine
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Currently hospitalized and requiring medical care for non-sever COVID-19.
* One or more of the following: (positive PCR test or positive antibodies) or (CT Chest consistent with COVID19 infection).
Exclusion Criteria
* Mechanical ventilation
* Requirement of oxygen supplementation \>8L/min on admission
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ain Shams University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ain Shams University hospitals
Cairo, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FAMSU R 179 / 2021
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.